Research & Development


  • Moderna company name on side of building
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Q&A

    For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

    Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

    By Feb. 23, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • chemist in lab with dropper
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 biotechs to watch in 2024

    A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

    By Alexandra Pecci • Feb. 21, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • IoT and AI design
    Image attribution tooltip
    Permission granted by Avenga
    Image attribution tooltip
    Sponsored by Avenga

    Value and potential of IoT and AI for chronic diseases treatment

    A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

    By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024
  • paper pie chart hand placing a piece
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma CFOs need R&D vigilance in tough economic times

    Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

    By Feb. 16, 2024
  • pill loading
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Brain MRI
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Dr. Robert Califf, FDA commissioner, speaking at a podium with hands up
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    FDA inches closer to defining its regulatory role in AI

    Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

    By Feb. 12, 2024
  • Yoshi Shitaka
    Image attribution tooltip
    Permission granted by Astellas
    Image attribution tooltip

    Astellas’ science chief on the leap into new technologies

    After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

    By Feb. 9, 2024
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

    While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

    By Feb. 8, 2024
  • rocket ship blasting into space with stars and clouds
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Vaxxinity is brewing up meds for a spacefaring future

    The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

    By Kelly Bilodeau • Feb. 5, 2024
  • Dr. Marcel van den Brink, President, City of Hope Cancer Center
    Image attribution tooltip
    Permission granted by City of Hope
    Image attribution tooltip

    Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

    The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.  

    By Jan. 31, 2024
  • AZ vaccine
    Image attribution tooltip
    Ricardo Ceppi via Getty Images
    Image attribution tooltip

    Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

    Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

    By Alexandra Pecci • Jan. 30, 2024
  • neck pain stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tonix closes in on the first new fibromyalgia drug in more than a decade

    In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

    By Kelly Bilodeau • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By Jan. 25, 2024
  • MRI machine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Breast cancer tops list of most studied diseases

    The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

    By Kelly Bilodeau • Jan. 24, 2024
  • Coronavirus
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    The hunt for an elusive universal coronavirus vaccine

    A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

    By Alexandra Pecci • Jan. 22, 2024
  • hand syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Controversial challenge trials offer unparalleled innovation — with ethical bumps

    Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

    By Kelly Bilodeau • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By Jan. 19, 2024
  • gut microbiome
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma takes a gut check of microbiome drugs

    On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

    By Kelly Bilodeau • Jan. 16, 2024
  • San Francisco
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Pharma execs sound off on trends and policies they’re tracking in 2024

    From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

    By Jan. 12, 2024